[
    [
        {
            "time": "",
            "original_text": "先于KKR、高瓴，打通42万家“门店”，百洋医药如何打造千亿生意",
            "features": {
                "keywords": [
                    "百洋医药",
                    "门店",
                    "千亿生意"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药零售"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "先于KKR、高瓴，打通42万家“门店”，百洋医药如何打造千亿生意",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药与健康护理行业信息点评：体内CRISPR基因编辑首个临床试验公布",
            "features": {
                "keywords": [
                    "CRISPR",
                    "基因编辑",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药与健康护理行业信息点评：体内CRISPR基因编辑首个临床试验公布",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报：第五批国家集采报价结束 看好不受集采影响的高壁垒创新和服务赛道",
            "features": {
                "keywords": [
                    "国家集采",
                    "高壁垒创新",
                    "服务赛道"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药制造",
                    "医疗服务"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药行业周报：第五批国家集采报价结束 看好不受集采影响的高壁垒创新和服务赛道",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "药明康德寻求出售2300万股药明巨诺股份",
            "features": {
                "keywords": [
                    "药明康德",
                    "药明巨诺",
                    "股份出售"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德寻求出售2300万股药明巨诺股份",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "药明康德寻求出售2300万股药明巨诺股份 资产异常",
            "features": {
                "keywords": [
                    "药明康德",
                    "药明巨诺",
                    "资产异常"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德寻求出售2300万股药明巨诺股份 资产异常",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "新发现！Immunity揭示神药二甲双胍在新冠肺炎中的作用机制；罗氏诊断携手金橡医学，助力精准医疗的持续创新丨贝壳日报",
            "features": {
                "keywords": [
                    "二甲双胍",
                    "新冠肺炎",
                    "精准医疗",
                    "罗氏诊断"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "精准医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "新发现！Immunity揭示神药二甲双胍在新冠肺炎中的作用机制；罗氏诊断携手金橡医学，助力精准医疗的持续创新丨贝壳日报",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "通化东宝：目前申报的三靶点抑制剂产品已获临床试验批准书",
            "features": {
                "keywords": [
                    "通化东宝",
                    "三靶点抑制剂",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "通化东宝：目前申报的三靶点抑制剂产品已获临床试验批准书",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "明德生物：公司目前暂未与药明康德进行合作",
            "features": {
                "keywords": [
                    "明德生物",
                    "药明康德",
                    "合作"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "明德生物：公司目前暂未与药明康德进行合作",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药市值一哥退居老三 恒瑞医药7个创新药获批上市",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "创新药",
                    "市值排名"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药市值一哥退居老三 恒瑞医药7个创新药获批上市",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围 连续下跌",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "药品集采",
                    "创新药",
                    "连续下跌"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药市值掉队年内蒸发1876亿 深陷“药品集采”困局欲借创新药突围 连续下跌",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        }
    ]
]